StevenKysungSeungMDPhD, FACR
Radiation Oncology • Portland, ORMedical Director, The Gamma Knife Center of Oregon
Dr. Seung is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4805 Ne Glisan St
Garden Level
Portland, OR 97213Phone+1 503-215-6029Fax+1 503-215-6387
Education & Training
University of California (San Francisco)Residency, Radiation Oncology, 1995 - 1998
Ascension Illinois/Saint Joseph (Chicago)Internship, Internal Medicine, 1994 - 1995
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1994
Certifications & Licensure
CA State Medical License 1996 - Present
OR State Medical License 1998 - 2025- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2010-2014
- America's Top Doctors for Cancer Castle Connolly, 2009-2013
- CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013
- Join now to see all
Clinical Trials
- Selective Dose Escalation for Esophageal Cancer Start of enrollment: 2000 Jul 01
- Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer Start of enrollment: 2010 Oct 14
- Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions Start of enrollment: 2012 Apr 27
- Join now to see all
Publications & Presentations
PubMed
- 32 citationsRandomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma.Brendan D. Curti, Marka R. Crittenden, Steven K. Seung, Christopher B. Fountain, Roxanne Payne
Journal for Immunotherapy of Cancer. 2020-05-01 - 237 citationsPhase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2—Tumor and Immunological ResponsesSteven K. Seung, Brendan D. Curti, M.R. Crittenden, Edwin B. Walker, Todd Coffey
Science Translational Medicine. 2012-06-06 - 4 citationsPhase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected ...Steven K. Seung, Helen J. Ross
International Journal of Radiation Oncology, Biology, Physics. 2009-03-01
Press Mentions
Providence Offers Breakthrough Radiation Technology to Cancer PatientsJuly 10th, 2020- Providence Portland Medical Center Begins Patient Treatments with ViewRay's MRIdian LinacMay 27th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
